Background
==========

In men, prostate cancer (PCa) is the most frequently diagnosed malignancy in industrialized countries \[[@B1]\] and it is the second most commonly diagnosed cancer and the sixth leading cause of cancer death worldwide \[[@B2]\]. There is a clear need for a better understanding of the risk factors related to PCa development and progression. Age, race and family history are the only established prostate cancer risk factors and these factors are all non-modifiable. Recently, modifiable lifestyle factors such as physical activity and diet have been investigated. Because a higher incidence of PCa was associated with a higher prevalence of "western" lifestyle, it has been suggested that these lifestyle factors play a significant role in the pathogenesis of PCa \[[@B3]\].

Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors that includes hypertension, diabetes mellitus, obesity, hypertriglyceridemia, and low high-density lipoprotein cholesterol, with insulin resistance as the underlying hallmark feature \[[@B4]\]. The prevalence of MetS has been increasing worldwide and has become a major public health problem in many western countries. For example, 35%-41% of adults in the USA are reported to exhibit MetS \[[@B5]\]. Recently, increasing evidences suggests that MetS may be involved in the development and progression of certain types of cancer as an independent etiologic factor including breast cancer \[[@B6]\], endometrial cancer \[[@B7]\], colorectal cancer \[[@B8]\], pancreatic cancer \[[@B9]\] and prostate cancer \[[@B10]\]. MetS was firstly observed as a composite factor associated with prostate cancer risk in 2004 \[[@B11]\], and more studies have since reported the association between MetS and prostate cancer. However, the studies investigating the association between MetS and prostate cancer risk have reported inconsistent findings \[[@B12]-[@B21]\].

It is crucial to review and evaluate the magnitude to which MetS affects the development and progression of PCa, as proper management of this modifiable lifestyle factor may help improve PCa outcomes.

A recently performed meta-analysis study summarized the association between MetS and the incidence of some common cancer types, including prostate cancer. The results, based on 14 databases, revealed that MetS was not associated with prostate cancer risk \[[@B22]\]. However, a new investigation on MetS and prostate cancer risk was published recently \[[@B19]\], and much increasing evidence in the latest investigations suggests that MetS may be associated with the aggressiveness and progression of PCa; prostate cancer patients with MetS may suffer more aggressive disease and adverse clinical outcomes \[[@B19],[@B23]-[@B27]\]. However, inverse results \[[@B28]\] or no significant associations \[[@B14],[@B20],[@B29],[@B30]\] have been reported in other studies. Therefore, to thoroughly investigate the nature of this association, we focused on longitudinal cohort studies and conducted a new meta-analysis to confirm the association between MetS and prostate cancer risk by searching the latest literature. Subsequently, we performed another meta-analysis to quantitatively summarize several parameters of PCa aggressiveness and progression, including Gleason score, clinical stage, biochemical recurrence and prostate cancer-specific mortality associated with MetS.

Methods
=======

Search strategy
---------------

We systematically searched MEDLINE, EMBASE through January 2013 for human studies on the association between MetS and PCa with the following medical subject heading terms and/or text words: "metabolic syndrome", "insulin resistance syndrome", or "syndrome X", combined with "prostate cancer", "prostatic cancer", "prostate neoplasm", or "prostatic neoplasm". We also manually searched relevant journals, bibliographies, and reviews for additional articles. The search had no language restriction.

Inclusion criteria
------------------

The eligibility of each study was assessed independently by two investigators (YX and HX). We included only cohort studies of MetS and prostate cancer risk or prostate cancer-specific mortality and clinical studies of MetS and Gleason score or clinical stage at diagnosis or biochemical recurrence after treatment. We included studies that reported standardized forms of relative risk, risk ratio, hazard ratio or odds ratio with estimates of confidence intervals (CIs) or with sufficient data to estimate CIs. We used relative risks (RRs) to represent various effect estimates in a cohort study in this meta-analysis.

Exclusion criteria
------------------

We excluded reviews, editorials, meta-analysis and animal studies. Among the 23 studies that underwent full-text reviews, we excluded a study on MetS and prostate cancer risk of re-biopsy \[[@B31]\], a study that did not use a standard definition of MetS \[[@B32],[@B33]\] and one case-control study on MetS and prostate cancer risk \[[@B21]\]. For studies previously published on the same database \[[@B34],[@B35]\], we included only the most recent findings \[[@B19],[@B20]\]. All of the studies on which we focused reported RRs with 95% CIs or sufficient data to estimate them.

Data extraction
---------------

The data extracted included publication data (the first author's last name, year of publication, and country of the population studied), study design, population resources, number of cases, risk estimates with their corresponding CIs, and variables controlled for by matching or in the most adjusted model. Abstractions of the data elements were conducted separately by two authors; discordant results were resolved by consensus.

Statistical analysis
--------------------

Firstly, we updated the data and attempted to analyze the association of MetS with the prostate cancer risk in longitudinal cohort studies only. Subsequently, we assessed the association between MetS and prostate cancer-specific mortaligy in cohort studies and between MetS and high grade Gleason PCa and/or advanced PCa or biochemical recurrence in clinical studies. We pooled all of the RRs for MetS and assessed the heterogeneity between the studies by Q and I^2^ statistics, which are distributed as x^2^ statistics \[[@B36]\]. A value of P \< 0.10 was used to indicate lack of homogeneity (heterogeneity) among effects. We used a fixed-effects model if I^2^ value significance was \<0.1; otherwise, we used a random-effect model. Sensitivity analysis was conducted by omitting one study at a time, generating the pooled estimates and comparing with the original estimates. Funnel plots and both Begg's and Egger's tests were used to evaluate publication bias. All analyses were performed using STATA version 9.0 statistical software (Stata, College Station, Texas, USA). All statistical comparisons were 2-sided, and a p-value \< 0.05 was considered statistically significant).

Results
=======

Study characteristics
---------------------

Nineteen studies met the search inclusion and exclusion criteria. The characteristics of included studies are presented in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### 

Characteristics of cohort studies of metabolic syndrome and prostate cancer risk

   **Author yr (ref. no.)**     **Country**                 **Population**                **Mean age, yr**   **Mean FU time, yr**   **Time period**   **Cohort size**           **Definition of MetS**           **No. of cases**   **RRs**   **95% CI**   **Controlled variables**
  --------------------------- --------------- ------------------------------------------ ------------------ ---------------------- ----------------- ----------------- ---------------------------------------- ------------------ --------- ------------ --------------------------
   Laukkanen 2004 \[[@B11]\]      Finland                 Kuopio communities                    52.6                  15               1984-2001           1,880                         WHO                            56          RR 1.90    1.1-3.5               Age
     Tande 2006 \[[@B12]\]     United States   ARIC\* (49% white, 51% African American)        45-64                 12.1              1987-2000           6,429                     NCEP-ATP-III                      385          RR 0.77   0.60-0.98           Age, race
     Russo 2008 \[[@B13]\]         Italy         A pharmacologically based diagnosis             40                  2.7               1999-2005            NA           A pharmacologically based diagnosis            94          RR 0.93   0.75-1.14              Age
    Martin 2009 \[[@B14]\]        Norway                        HUNT2                        48 ± 16.4               9.3               1996-2005          29,364                     NCEP-ATP-III                      687          RR 0.91   0.77-1.09              Age+
     Inoue 2009 \[[@B15]\]         Japan                 Japan PHC population                  40-69                 10.2              1993-2004           9,548                         IDF                           119          HR 0.76   0.47-1.22              Age+
   Grundmark 2010 \[[@B16]\]      Sweden                        ULSAM                            50                  30.3              1970-2003           2,183                     NCEP-ATP-III                      226          RR 1.29   0.89-1.88              Age
             2,287                  IDF                          234                          RR 1.18             0.81-1.71                                                                                                                               
    Wallner 2010 \[[@B17]\]    United States                Olmsted County                     40-79                  15                1990-NA            2,445                         WHO                           206          HR 0.65   0.37-1.10              Age
     Osaki 2011 \[[@B18]\]         Japan         The population-based cancer registry       60.5 ± 10.8              9.3               1992-2007           8,239                     NCEP-ATP-III                      152          HR 1.37   0.91-2.06              Age
             8,239                  IDF                          152                          HR 1.18             0.74-1.90                                                                                                                               
   Häggström 2012 \[[@B19]\]      Norway                        Me-Can                           44                   12                  NA              289,866       Upper quartile levels ATP-III criteria        6,922         RR 0.96   0.92-1.00              Age+
            Sweden                                                                                                                                                                                                                                        
            Austria                                                                                                                                                                                                                                       

*MetS* = metabolic syndrome; *PCa* = prostate cancer; *RRs* = Relative risks; *CI* = confidence interval; *Age* + =At least age; *WHO* = World Health Organization; *NCEP-ATP-III* = National Cholesterol Education Program Adult Treatment Panel III; *IDF* = International Diabetes Federation; *HUNT 2* = Nord-Trondelang Health Study; *ARIC* = Atherosclerosis Risk in Communities; *OR* = odds ratio; \*We use White-American data.

###### 

Characteristics of studies of metabolic syndrome and parameters of prostate cancer

        **Author yr (ref. no.)**             **Country**         **Study design**                                  **Population**                                 **Mean age,yr**   **Time period**          **Definition Vof MetS**           **No. of cases**        **Outcomes**         **RRs**   **95% CI**
  ------------------------------------ ----------------------- --------------------- --------------------------------------------------------------------------- ----------------- ----------------- ---------------------------------------- ------------------ ------------------------- --------- -------------
          B.K 2007 \[[@B29]\]                   Korea           Cross-section study            Patients who underwent radical retropubic prostatectomy              64.8 ± 6.2         2004-2006                   NCEP-ATP-III                      261          Gleason score ≥7(4 + 3)    0.972    0.637-1.482
          Clinical stage ≥ T3                   0.991               0.532-1.846                                                                                                                                                                                                                      
      Beebe-Dimmer 2009 \[[@B20]\]          United States       Case-control study                                      GECAP                                          62.3            1999-2004                   NCEP-ATP-III                      637          Gleason score ≥7(4 + 3)     1.2      0.64-2.27
          Clinical stage ≥ T3                   1.17                 0.55-2.51                                                                                                                                                                                                                       
   Castillejos-Molina 2011 \[[@B23]\]          Mexico           Case-control study                Patients with PC who underwent surgical treatment                 64.8 ± 6.97        1990-2007                       WHO                           210             Gleason score \>7       3.346    1.144-9.791
          Clinical stage ≥ T3                   1.628               0.915-2.896                                                                                                                                                                                                                      
       Kheterpal 2012 \[[@B24]\]            United States       Cross-section study          Patients who underwent robot assisted radical prostatectomy            60.7 ± 6.9         2005-2008                       IDF                           2756         Gleason score ≥7(4 + 3)    1.328    0.978-1.802
          Clinical stage ≥ T3                   1.416               1.109-1.808                                                                                                                                                                                                                      
       De Nunzio 2011 \[[@B25]\]                Italy           Cross-section study   Patients who underwent prostate biopsy for PSA \> 4 ng/ml or abnormal DRE         69             2009-2011                   NCEP-ATP-III                       83             Gleason score ≥7        3.82      1.33-10.9
          Clinical stage ≥ T3                    NA                     NA                                                                                                                                                                                                                           
          Jeon 2012 \[[@B28]\]                  Korea           Cross-section study   Patients who underwent prostate biopsy for PSA \> 4 ng/ml or abnormal DRE    68.86 ± 8.95        2003-2011                   NCEP-ATP-III                       90          Gleason score ≥7(4 + 3)    0.101    0.022-0.473
          Clinical stage ≥ T3                    NA                     NA                                                                                                                                                                                                                           
         Morote 2012 \[[@B26]\]                 Spain           Cross-section study   Patients who underwent prostate biopsy for PSA \> 4 ng/ml or abnormal DRE      68(46-79)         2006-2010                   NCEP-ATP-III                      848             Gleason score \>7       1.75     1.260-2.414
          Clinical stage ≥ T3                    NA                     NA                                                                                                                                                                                                                           
   Castillejos-Molina 2011 \[[@B23]\]          Mexico           Case-control study                Patients with PC who underwent surgical treatment                 64.8 ± 6.97        1990-2007                       WHO                           210          Biochemical recurrence     2.73      1.65-4.50
          Post 2011 \[[@B27]\]              United States       Case-control study                  Patients who underwent radical prostatectomy                       60.9           1999- 2004                   NCEP-ATP-III                      383          Biochemical recurrence      1.5      0.90-2.6
        Jaggers 2009 \[[@B30]\]             United States          Cohort study                          Aerobics Center Longitudinal Study                            20-88           1977-2003                   NCEP-ATP-III                      185                 Mortality           1.32      0.63-2.77
         Martin 2009 \[[@B14]\]                Norway              Cohort study                                         HUNT2                                        48 ± 16.4         1996-2005                   NCEP-ATP-III                      107                 Mortality           0.81      0.52-1.25
       Häggström 2012 \[[@B19]\]        Norway Sweden Austria      Cohort study                                        Me-Can                                           44                NA          Upper quartile Levels ATP-III criteria         961                 Mortality           1.13      1.03-1.25

*PCa* = prostate cancer; *RRs* = Relative risks; *CI* = confidence interval; *WHO* = World Health Organization; *NCEP-ATP-III* = National Cholesterol Education Program Adult Treatment Panel III; *IDF* = International Diabetes Federation; *HUNT 2* = Nord-Trondelang Health Study; *NA* = Not available; *DRE* = Digital rectal examination.

Detailed search steps are described in Figure [1](#F1){ref-type="fig"}. Briefly, from the initial literature search we identified 547 abstracts. Twenty-three articles were considered of interest and full text of each article was retrieved for detailed evaluation. Eleven studies investigated the association between MetS and prostate cancer \[[@B11]-[@B21]\]. Nine of them were longitudinal cohort studies that reported the RRs of PCa in cancer-free population with and without MetS \[[@B7]-[@B15]\]. Seven studies evaluated MetS and pathological and clinical stages of PCa, of these studies, 7/7 investigate Gleason score \[[@B20],[@B23]-[@B26],[@B28],[@B29]\] and 4/7 investigated clinical stage \[[@B20],[@B23],[@B24],[@B29]\]. Two case-control studies explored biochemical recurrence after primary treatment \[[@B23],[@B27]\], and three longitudinal cohort studies focused on prostate cancer-specific mortality \[[@B14],[@B19],[@B30]\].

![Selection of studies for meta-analysis.](1756-9966-32-9-1){#F1}

Main findings
-------------

### Prostate cancer risk

Result from a meta-analysis based on nine longitudinal cohort studies revealed that there was no association between MetS and prostate cancer risk (RR = 0.96, 95% CI 0.85-1.09 n = 9 studies) (Figure [2](#F2){ref-type="fig"}).

![RR of prostate cancer risk for MetS presence.](1756-9966-32-9-2){#F2}

### Prostate cancer aggressiveness

#### High grade Gleason score

The definition of high grade Gleason score is ≥ 7 or \> 7. A trend for a 36% increased risk of a high Gleason score in patients with MetS (OR = 1.36, 95% CI 0.90-2.06 n = 7 studies) was identified based on a meta-analysis of seven total relative databases (Figure [3](#F3){ref-type="fig"}).

![RR of high grade Gleason prostate cancer risk for MetS presence.](1756-9966-32-9-3){#F3}

#### Advanced clinical stage

Advanced clinical stage was defined as a clinical stage ≥ T3. Four databases were included in the analysis of the association of MetS with advanced clinical stage. The analysis revealed that MetS was significantly associated with a 37% increased risk of advanced clinical stage (OR = 1.37, 95% CI: 1.12 \~ 1.68; n = 4 studies) (Figure [4](#F4){ref-type="fig"}).

![RR of advanced clinical stage for MetS presence.](1756-9966-32-9-4){#F4}

### Prostate cancer progression

#### Biochemical recurrence

Only two databases \[[@B23],[@B27]\] focused on the association of MetS which biochemical recurrence. The Individual study results and the overall summary results are presented in Figure [5](#F5){ref-type="fig"}. The result indicates that MetS was significantly associated with 2-folds of increased risk of biochemical recurrence (OR = 2.06, 95% CI: 1.43-2.96, n = 2 studies).

![RR of biochemical recurrence for MetS presence.](1756-9966-32-9-5){#F5}

#### Prostate cancer-specific mortality

Three cohort studies \[[@B14],[@B19],[@B30]\] investigated how MetS affected prostate cancer-specific mortality. The meta-analysis revealed that MetS was significantly associated with a higher risk of the prostate cancer-specific death (RR = 1.12, 95% CI: 1.02 \~ 1.23; n = 3 studies) (Figure [6](#F6){ref-type="fig"}).

![RR of prostate cancer-specific mortality for MetS presence.](1756-9966-32-9-6){#F6}

Sensitivity analysis
--------------------

We conducted sensitivity analysis by omitting one study at a time, generating the pooled estimates and comparing the pooled estimates with the original estimates. Omitting any one of nine studies concerning MetS and prostate cancer risk or omitting any one of four studies concerning MetS and advanced clinical stage produced no dramatic influence on the original pooled RRs. Omitting Jeon 2012 database \[[@B28]\] in the 7 studies concerning MetS and Gleason score produced a significant OR = 1.44 (95% CI: 1.20 \~ 1.72), whereas none of the remaining severn studies exhibited a significant influence on the original estimates. For biochemical recurrence and prostate cancer-specific mortality, there were too few studies to do a sensitivity analysis.

Publication bias
----------------

Visual inspection of the Begg funnel plot for both PCR and Gleason score did not reveal the asymmetry typically associated with publication bias (Figure [7](#F7){ref-type="fig"}). Evidence of publication bias was also not seen with the Egger or Begg tests (Egger P = 0.27 and 0.64 for prostate cancer risk and Gleason score respectively).

![Funnel plot with pseudo 95% confidence limits.](1756-9966-32-9-7){#F7}

Discussion
==========

In 2007, Hsing et al. summarized five studies on MetS and prostate cancer risk and concluded that the epidemiologic evidence was insufficient to suggest a link between MetS and PCa \[[@B37]\]. In 2012, Esposito et al. performed a systematical review and meta-analysis on the association of MetS and cancer risk including prostate cancer. The authors also concluded that MetS was not associated with prostate cancer risk too \[[@B22]\]. In the present study, we updated the data and used the current evidence to analyze whether MetS is associated with prostate cancer risk. We observed the same result as previous meta-analysis; no association could be detected between Mets and prostate cancer.

We believe the result is reliable for two reasons. Firstly, only longitudinal cohort studies were included in this analysis, imparting strong evidence for our conclusions. In addition, the association between MetS and prostate cancer may be affected by several factors, including heterogeneity among the individual studies. The heterogeneity may arise from differences in age, race, the definition of MetS \[[@B22]\], and geographic factors \[[@B26]\]. Further, MetS is a syndrome composed of at least 3 components, and the individual component may exert antagonistic functions on one another Thus the syndrome may represent an integrated outcome that combines neutralizing positive and negative functions. For example, a meta-analysis revealed that diabetes mellitus was significantly negatively associated with prostate cancer risk in population-based studies (RR = 0.72, 95% CI: 0.64-0.81) and cohort studies conducted in the USA (RR = 0.79, 95% CI: 0.73, 0.86) \[[@B38]\]. Furthermore, several genome-wide association studies suggest that diabetes mellitus and prostate cancer share certain genetic factors, including the *HNF1β* and *JAZF1* genes, and a previous study suggested that *JAZF1* might represent a potential target against diabetes and obesity \[[@B39]\]. Although hypertension was found to be positively associated with prostate cancer risk \[[@B33],[@B40]-[@B42]\], Obesity is negatively with localized prostate cancer (0.94, 95% CI, 0.91-0.97) and positively associated with advanced prostate cancer risk (1.07, 95% CI 1.01-1.13) \[[@B43]\].

However, after analyses of several parameters of PCa aggressiveness and progression, we found MetS to be significantly associated with an increased risk of prostate cancer with a high-Gleason score or advanced clinical stage, with biochemical recurrence after primary treatment and with prostate cancer-specific mortality. If confirmed by more investigations, this finding may open a new research field on PCa development and progression, potentially leading to new strategies or methods for PCa treatment. MetS is a major public health problem and prostate cancer is the most prevalent solid organ tumor, accounts for 29% of all cancer cases and the second most common cause of death by cancer among men in the USA \[[@B44]\]. Therefore we believe that there is a compelling need to investigate this association between MetS and prostate cancer although the association is not strong.

Nevertheless, the reliability of these results is limited. First, Gleason score and clinical stage data were extracted from cross-sectional studies not longitudinal cohort studies. Second, there exists a small difference among studies on the definition of high-grade Gleason PCa, some authors defined a high Gleason score ≥ 7 whereas others defined a high score as \>7. Third, the pathological stage data in some studies were from biopsy not radical prostatectomy specimens. Last but not least, to date there remains limited studies focusing on this association, although many of the available studies are well designed case-control or longitudinal cohort studies.

In addition to the limitations listed above, another limitation for the analyses of the association between MetS and prostate cancer risk or prostate cancer parameters is that we did not perform a meta-regression to attempt to explain the heterogeneity of the study because of the varying adjustments in the individual studies. The result of a recent meta-analysis on 9 cross-sectional studies of metabolic syndrome in adult cancer survivors increases the weight of this suspicion, as it revealed that no significant association was found for non-hematologic malignancies, including testicular tumor, prostate cancer, sarcoma, and epithelial ovarian \[[@B45]\]. Therefore, there is an urgent future need to confirm this association and to find potential mechanisms to explain how metabolic factors affect the development or progression of PCa.

Conclusions
===========

Based on the current findings, MetS is not associated with prostate cancer risk, but preliminary evidences demonstrates that men with MetS more frequently suffer high-grade prostate cancer, more advanced disease and are at greater risk of progression after radical prostatectomy and prostate cancer-specific death. Together, these findings indicate that MetS may be associated with the progression of prostate cancer and adverse clinical outcomes. Further studies with adjustment for appropriate confounders and larger, prospective, multicenter investigations are required in the future.
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